The Manufacturers Life Insurance Company Takes $57,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

The Manufacturers Life Insurance Company bought a new position in scPharmaceuticals Inc. (NASDAQ:SCPH) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,411 shares of the company’s stock, valued at approximately $57,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. King Luther Capital Management Corp increased its stake in scPharmaceuticals by 0.9% in the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock worth $10,150,000 after acquiring an additional 20,650 shares during the last quarter. Thrivent Financial for Lutherans increased its position in scPharmaceuticals by 1.4% in the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock worth $4,783,000 after purchasing an additional 14,866 shares during the last quarter. Rice Hall James & Associates LLC increased its position in scPharmaceuticals by 25.0% in the third quarter. Rice Hall James & Associates LLC now owns 621,665 shares of the company’s stock worth $2,835,000 after purchasing an additional 124,438 shares during the last quarter. Bank of Montreal Can purchased a new stake in scPharmaceuticals during the second quarter valued at $1,544,000. Finally, AIGH Capital Management LLC lifted its position in scPharmaceuticals by 3.4% during the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock valued at $15,244,000 after purchasing an additional 115,206 shares during the last quarter. 89.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on SCPH shares. Craig Hallum reduced their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, November 14th.

scPharmaceuticals Stock Up 1.6 %

Shares of SCPH opened at $3.25 on Wednesday. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The business has a fifty day moving average of $3.88 and a 200 day moving average of $4.36. The company has a market cap of $162.63 million, a PE ratio of -1.71 and a beta of 0.14. scPharmaceuticals Inc. has a 52-week low of $3.08 and a 52-week high of $6.71.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.